Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling.

Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C.

Biol Psychiatry. 2000 May 1;47(9):813-7.

PMID:
10812040
2.

Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.

Black DW, Arndt S, Coryell WH, Argo T, Forbush KT, Shaw MC, Perry P, Allen J.

J Clin Psychopharmacol. 2007 Apr;27(2):143-50.

PMID:
17414236
3.

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.

Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L.

Eur Neuropsychopharmacol. 2005 Jan;15(1):69-74.

PMID:
15572275
4.
5.

A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.

Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM.

J Clin Psychiatry. 2003 Jun;64(6):640-7.

PMID:
12823077
6.

A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.

Milanfranchi A, Ravagli S, Lensi P, Marazziti D, Cassano GB.

Int Clin Psychopharmacol. 1997 May;12(3):131-6.

PMID:
9248868
7.

A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.

Otsubo T, Akimoto Y, Yamada H, Koda R, Aoyama H, Tanaka K, Mimura M, Nakagome K, Kamijima K.

Pharmacopsychiatry. 2005 Jan;38(1):30-5.

PMID:
15706464
8.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
9.
10.

Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.

Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, Barbato LM, van der Hoop RG, Li D.

J Clin Psychopharmacol. 2004 Apr;24(2):118-25.

PMID:
15206657
11.

Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.

Goodman WK, Kozak MJ, Liebowitz M, White KL.

Int Clin Psychopharmacol. 1996 Mar;11(1):21-9.

PMID:
8732310
12.
13.

An open-label trial of escitalopram in the treatment of pathological gambling.

Black DW, Shaw M, Forbush KT, Allen J.

Clin Neuropharmacol. 2007 Jul-Aug;30(4):206-12.

PMID:
17762317
14.

Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.

Mundo E, Guglielmo E, Bellodi L.

Int Clin Psychopharmacol. 1998 Sep;13(5):219-24.

PMID:
9817627
15.
16.

Short-term single-blind fluvoxamine treatment of pathological gambling.

Hollander E, DeCaria CM, Mari E, Wong CM, Mosovich S, Grossman R, Begaz T.

Am J Psychiatry. 1998 Dec;155(12):1781-3.

PMID:
9842795
17.

Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying.

Ninan PT, McElroy SL, Kane CP, Knight BT, Casuto LS, Rose SE, Marsteller FA, Nemeroff CB.

J Clin Psychopharmacol. 2000 Jun;20(3):362-6.

PMID:
10831025
18.

Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.

Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ.

J Clin Psychiatry. 1994 Jul;55(7):301-5.

PMID:
8071291
19.

Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.

Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A.

J Clin Psychopharmacol. 2006 Apr;26(2):152-6.

PMID:
16633143
20.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525

Supplemental Content

Support Center